Study on Prostate Salvage Using High-dose-rate Brachytherapy (PROSCATE)
Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.
研究概览
地位
详细说明
The objectives of this prospective, multicenter study are:
-
Primary:
1. Biochemical relapse-free survival, defined as the time to biochemical relapse (nadir plus 2 ng/mL - Phoenix criteria).
-
Secondary:
- Local relapse-free survival, defined as the time from treatment to local relapse confirmed by imaging (choline PET/MRI).
- Analysis of acute and chronic toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version 5).
- Assessment of patient quality of life before and after treatment to analyze the impact of local re-irradiation on daily life using the following questionnaires: International Prostate Symptom Score (IPSS), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Module (EORTC QLQ-PR25).
Primary outcome measure: Biochemical relapse-free survival, and analysis of toxicity and quality of life in patients treated with salvage brachytherapy following radical treatment.
Study population, total number of subjects, and duration: Patients who received radical-intent radiotherapy as their initial treatment (brachytherapy alone, external beam radiotherapy, or external beam radiotherapy plus a brachytherapy boost) and were diagnosed with local recurrence via next-generation imaging techniques (choline PET/PSMA PET) and prior biopsy; these patients are scheduled to undergo salvage brachytherapy as part of routine clinical practice. A calculated sample size of 63 patients will be reached over a 2-year recruitment period. Follow-up will be conducted according to standard clinical practice every 6 months for the 4-year duration of the study.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Patricia Willisch Santamaría, MD PhD
- 电话号码:986 811 714
- 邮箱:patricia.willisch.santamaria@sergas.es
研究联系人备份
- 姓名:Pablo Raña Díez
- 电话号码:914009600
- 邮箱:investigacion@seor.es
学习地点
-
-
Alicante
-
Benidorm、Alicante、西班牙、03501
- 招聘中
- Hospital HCB Benidorm
-
接触:
- Silvia Rodríguez Villalba, MD
- 电话号码:965 85 38 50
- 邮箱:srodriguez@clinicabenidorm.com
-
首席研究员:
- Silvia Rodríguez Villalba, MD
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、西班牙、08908
- 招聘中
- Instituto Catalán de Oncología L'Hospitalet
-
接触:
- Andrea Slocker Escarpa, MD
- 电话号码:932607733
- 邮箱:andrea.slocker@iconcologia.net
-
首席研究员:
- Andrea Slocker Escarpa, MD
-
-
Cantabria
-
Santander、Cantabria、西班牙、39008
- 招聘中
- Hospital Universitario Marqués de Valdecilla
-
接触:
- Ana Soledad García Blanco, MD
- 电话号码:942 20 25 20
- 邮箱:anasoledad.garcia@scsalud.es
-
首席研究员:
- Ana Soledad García Blanco, MD
-
-
Córdoba
-
Córdoba、Córdoba、西班牙、14004
- 招聘中
- Hospital Universitario Reina Sofía
-
接触:
- Sonia García Cabezas, MD
- 电话号码:957 010 000
- 邮箱:sonia.garcia.cabezas.sspa@juntadeandalucia.es
-
首席研究员:
- Sonia García Cabezas, MD
-
-
Guipuzcoa
-
San Sebastián、Guipuzcoa、西班牙、20014
- 尚未招聘
- Instituto Oncológico de San Sebastián (Onkologikoa)
-
接触:
- Alai Goñi Ramírez, MD
- 电话号码:943 32 80 00
- 邮箱:agoni@onkologikoa.org
-
首席研究员:
- Alai Goñi Ramírez, MD
-
-
Madrid
-
Madrid、Madrid、西班牙、28034
- 招聘中
- Hospital Universitario Ramón y Cajal
-
接触:
- María Teresa Muñoz Migueláñez, MD
- 电话号码:91 336 84 34
- 邮箱:mmmiguelanez@salud.madrid.org
-
首席研究员:
- María Teresa Muñoz Migueláñez, MD
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- 招聘中
- Hospital Universitario de Navarra
-
接触:
- Ignacio Visus Fernández de Manzano, MD
- 电话号码:848 42 21 60
- 邮箱:ignacio.visus.fdezdemanzano@navarra.es
-
首席研究员:
- Ignacio Visus Fernández de Manzano, MD
-
-
Pontevedra
-
Vigo、Pontevedra、西班牙、36312
- 招聘中
- Hospital Meixoeiro
-
接触:
- Patricia Willisch Santamaría, MD PhD
- 电话号码:986 811 714
- 邮箱:patricia.willisch.santamaria@sergas.es
-
首席研究员:
- Patricia Willisch Santamaría, MD
-
-
Valencia
-
Valencia、Valencia、西班牙、46026
- 招聘中
- Hospital Universitario y Politécnico La Fe
-
接触:
- Francisco Javier Celada Álvarez, MD
- 电话号码:961 24 40 00
- 邮箱:celada_fra@gva.es
-
首席研究员:
- Francisco Javier Celada Álvarez, MD
-
-
Vizcaya
-
Barakaldo、Vizcaya、西班牙、48903
- 尚未招聘
- Hospital Universitario de Cruces
-
接触:
- David Büchser García, MD
- 电话号码:946 006 591
- 邮箱:david.buechsergarcia@osakidetza.eus
-
首席研究员:
- David Büchser García, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients treated with radical-intent radiotherapy as their primary treatment (brachytherapy alone, external beam radiotherapy, or external beam radiotherapy plus a brachytherapy boost) who have been diagnosed with local recurrence via next-generation imaging techniques (Choline PET or PSMA PET) and prior biopsy, and who are to undergo salvage brachytherapy as part of routine clinical practice.
描述
Inclusion Criteria:
- Age over 18 years.
- Patients diagnosed with local recurrence confirmed by next-generation imaging and a positive biopsy.
- Hormone-sensitive patient.
- Patients whose initial treatment consisted of brachytherapy alone, external beam radiotherapy, or external beam radiotherapy with a prostate brachytherapy boost.
Exclusion Criteria:
- Metastatic disease.
- Castration-resistant prostate cancer, defined according to EAU (European Association of Urology) guidelines: A patient who progresses despite maintaining testosterone levels within the castration range (testosterone <50 ng/dL or <1.7 nmol/L) and presents with at least one of the following factors: Three consecutive rises in PSA (Prostate-Specific Antigen) levels, measured one week apart, representing two increases of 50% above the nadir, with a PSA level >2; PSA progression despite successive hormonal manipulations; Progression of bone lesions: progression or appearance of two or more bone lesions, or soft-tissue progression according to Response Evaluation Criteria in Solid Tumors (RECIST criteria).
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biochemical relapse-free survival
大体时间:From the date of salvage brachytherapy to 48 months after treatment
|
Time from salvage brachytherapy to biochemical recurrence of prostate cancer, defined according to the Phoenix definition as a rise in prostate-specific antigen (PSA) of ≥2 ng/mL above the post-treatment PSA nadir. Patients without biochemical recurrence will be censored at the date of their last available PSA assessment or at the end of the study follow-up. PSA measurements will be obtained at 1 month after treatment and subsequently every 6 months through 48 months. |
From the date of salvage brachytherapy to 48 months after treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Baseline Characteristics
大体时间:Baseline, Day 0
|
Initial disease characteristics: Initial PSA, Gleason/Grade Group, Stage Biopsy characteristics, Initial imaging, Initial treatment. Disease characteristics at recurrence: PSA at recurrence, prostate-specific antigen doubling time (PSADT), Location of recurrence, Recurrence biopsy, Urinary symptoms, Imaging findings |
Baseline, Day 0
|
|
Incidence of Late and Chronic Treatment-Related Toxicity
大体时间:From 1 month after salvage brachytherapy to 48 months after treatment
|
Incidence and severity of late and chronic treatment-related toxicity following salvage brachytherapy, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Toxicities will include genitourinary and gastrointestinal toxicities and other treatment-related adverse events identified during follow-up. |
From 1 month after salvage brachytherapy to 48 months after treatment
|
|
Local Relapse-Free Survival
大体时间:From the date of salvage brachytherapy to 48 months after treatment
|
Time from salvage brachytherapy to radiologically confirmed local recurrence of prostate cancer. Local recurrence will be assessed using imaging techniques, including prostate MRI, choline PET, and/or PSMA PET, according to routine clinical practice. Patients without radiologically confirmed local recurrence will be censored at the date of their last available imaging assessment or at the end of the study follow-up. |
From the date of salvage brachytherapy to 48 months after treatment
|
|
Incidence of Acute Treatment-Related Toxicity
大体时间:From the date of salvage brachytherapy to 1 month after treatment
|
Incidence and severity of acute treatment-related toxicity following salvage brachytherapy, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Acute toxicity will include genitourinary and gastrointestinal toxicities and other treatment-related adverse events occurring during the acute post-treatment period. |
From the date of salvage brachytherapy to 1 month after treatment
|
|
Change in International Prostate Symptom Score (IPSS) From Baseline
大体时间:Baseline and every 6 months after salvage brachytherapy through 48 months
|
Change in urinary symptoms assessed using the International Prostate Symptom Score (IPSS). The IPSS will be assessed before salvage brachytherapy and during follow-up every 6 months. The change from baseline will be evaluated over the study follow-up period. |
Baseline and every 6 months after salvage brachytherapy through 48 months
|
|
Change in Prostate Cancer-Specific Quality of Life (FACT-P) From Baseline
大体时间:Baseline and every 6 months after salvage brachytherapy through 48 months
|
Change in health-related quality of life assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. The FACT-P is a 39-item questionnaire assessing health-related quality of life in patients with prostate cancer. The total score ranges from 0 to 156, with higher scores indicating better health-related quality of life. The questionnaire will be administered before salvage brachytherapy and during follow-up every 6 months. Changes from baseline in the FACT-P total score will be evaluated throughout the study follow-up period. |
Baseline and every 6 months after salvage brachytherapy through 48 months
|
|
Change in Prostate Cancer-Specific Quality of Life (EORTC QLQ-PR25) From Baseline
大体时间:Baseline and every 6 months after salvage brachytherapy through 48 months
|
Change in prostate cancer-specific health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Module (EORTC QLQ-PR25). The EORTC QLQ-PR25 consists of 25 items scored on a 0 to 100 scale after linear transformation. Higher scores indicate greater symptom burden for symptom scales and higher levels of functioning or activity for the sexual activity/function scales. The questionnaire will be administered before salvage brachytherapy and during follow-up every 6 months. Changes from baseline in the EORTC QLQ-PR25 scores will be evaluated throughout the study follow-up period.. |
Baseline and every 6 months after salvage brachytherapy through 48 months
|
合作者和调查者
赞助
调查人员
- 研究主任:Patricia Willisch Santamaría, MD PhD、Galicia Sur Health Research Institute
- 学习椅:Pablo Raña Díez、Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- PROSCATE
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.